Stockwinners Market Radar for August 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 573K shares of Pacific Biosciences today

20:05 EDT Cathie Wood's ARK Investment bought 3.34M shares of Ginkgo Bioworks today

19:48 EDT F45 Training investor Kennedy Lewis Management buys $2.61M in common stock - In a regulatory filing, F45 Training disclosed that Kennedy Lewis Management bought 1.21M shares of common stock on August 18th in a total transaction size of $2.61M. Shares of F45 Training are up 6.5% afterhours.

19:02 EDT Canada Goose names Larry Li as President of Mainland China market - The company states: "Canada Goose announced the appointment of Larry Li as President, China, effective immediately. In this role, Li will oversee all business activities in the Mainland China market, including commercial, marketing and finance. He will be based out of the company's regional headquarters in Shanghai and report to Paul Cadman, President of Asia Pacific, Canada Goose. Li joins Canada Goose with nearly 20 years of experience in the luxury sector, having held regional senior leadership positions across retail, operations, and finance. Most recently, he was Managing Director, China at Dunhill, part of the Richemont Group, and was instrumental in the brand's repositioning and new product direction. This announcement comes as Canada Goose continues its expansion in the China market, which the company entered in 2018. Mainland China is home to Canada Goose's largest retail network, with 16 stores. In addition to the store that opened in Xi'an in May 2022, Canada Goose plans to open another three this fall in Tianjin, Qingdao and Chengdu."

18:28 EDT Sony says PSVR2 coming early 2023 - Sony said that PlayStation VR2, or PSVR2, will arrive in early 2023. Reference Link

18:07 EDT Owl Creek urges Cano Health to pursue strategic alternatives, including sale - Owl Creek Asset Management, on behalf of its affiliated investment funds, sent a letter to the Cano Health board of directors strongly encouraging the company to pursue strategic alternatives by engaging with investment bankers and other advisors to pursue a sale to a strategic buyer. "While we believe in the Company's business model and management's ability to execute the post "de-SPAC" business plan, the past year's roller coaster of accounting issues has shaken our confidence," the letter reads. "We feel that Cano's continued growth will require a larger and stronger vertically integrated partner with access to the capital needed to execute the Company's business plan. So, we were encouraged to hear on the second quarter earnings call that you are "open to considering all strategic alternatives to accelerate value creation." We strongly encourage you to actively pursue these strategic alternatives by engaging with investment bankers and other advisors to pursue a sale of the Company to a strategic buyer." As of August 19, 2022, Owl Creek owns 8,685,171 shares of Cano Health, representing 3.745% percent of the Class A equity of the company.

18:01 EDT Cryo-Cell announces special cash dividend of 90c per share - The dividend is to be paid to shareholders of record as of the close of business on September 2, 2022.

17:37 EDT FinVolution Group expands share repurchase program to $140M - FinVolution Group approved the expansion of FinVolution's existing share repurchase program from up to $60M to up to $140M and the extension for another twelve months from January 1, 2023 through December 31, 2023, which allows the company to repurchase its own Class A ordinary shares in the form of ADSs with an aggregate value of up to $140M until December 31, 2023. This share repurchase program was initially approved by the board of directors of the company on August 24, 2020 and an extension of the term of this share repurchase program until December 31, 2022 was approved by the board of directors of the company on November 17, 2021. FinVolution plans to fund the repurchases out of its existing cash balance or future cash provided by its operating activities.

17:22 EDT Atrion raises quarterly dividend from $1.95 to $2.15 per share - This dividend will be payable on September 30, 2022 to stockholders of record at the close of business on September 15, 2022.

17:05 EDT TJX exec Canestrari sells 29,977 common shares - In a regulatory filing, TJX senior executive VP and Group President Kenneth Canestrari disclosed the sale of 29,977 common shares of the company on August 18 at a price of $68 per share.

17:04 EDT TJX executive chairman Meyrowitz sells 70,720 common shares - In a regulatory filing, TJX executive chairman Carol Meyrowitz disclosed the sale of 70,720 common shares of the company on August 18 at a price of $67.6197 per share.

17:03 EDT Vistra appoints Stacey Dore as Chief Strategy & Sustainability Officer - Vistra announced that Stacey Dore will be joining the company as its first Chief Strategy and Sustainability Officer and Executive VP of Public Affairs, effective Aug. 23. Dore previously worked for Vistra's predecessor companies. Dore most recently served as President and CEO of Hunt Utility Services and Sharyland Utilities, an electric utility within the Electric Reliability Council of Texas market, from 2019-2021. Prior to that role, she was Senior VP and General Counsel for publicly traded InfraREIT. Dore originally joined Vistra's predecessor companies in 2008 as part of the legal team where she served in several leadership roles. Dore is a member of the board of directors for Williams energy infrastructure company.

16:48 EDT KKR invests in renewable energy developer Arevia Power - KKR (KKR) has led a significant structured investment in Arevia Power, a U.S. renewable energy developer, with strategic participation by GCM Grosvenor (GCMG). The investment aims to support the company's accelerated growth and development of new solar and wind projects throughout the U.S: Founded in 2015, Arevia is a solar and wind project developer that originates, permits, and manages renewable energy projects through their lifecycle. In tandem with the investment, Arevia has executed a Responsible Contractor Policy for its entire clean energy portfolio throughout the U.S. KKR is making its investment in Arevia from its managed insurance accounts. The investment from GCM Grosvenor will come from its infrastructure practice.

16:38 EDT DallasNews approves special $1.50 dividend, pension contribution - DallasNews' Board of Directors has approved a special dividend of $1.50 per share payable on September 30 to shareholders of record at the close of business on September 9. The Board also approved a voluntary contribution to the company's pension plans of $5M, which will be made prior to September 15, 2022. On July 29, the company received full payment of a note related to the 2019 sale of its former headquarters campus in Downtown Dallas. The total proceeds were $22.52M, which includes interest on the note. The amount of the special dividend being paid on September 30 is approximately $8M, which combined with the voluntary pension plan contribution totals approximately $13M. The remainder of the cash received from the headquarters note, approximately $10M, will be retained on the company's balance sheet. Following payment of the special dividend, cash on the balance sheet as of September 30 is projected to be approximately $33M.

16:32 EDT Adial Pharmaceuticals appoints Cary Claiborne CEO - Adial Pharmaceuticals announced the appointment of Cary Claiborne as president and CEO. Claiborne, who has 18 years of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies, takes over the role of William Stilley, who was appointed to the newly created position of CEO of Purnovate. Both executives will remain on the board of Adial. The company also announced that Kevin Schuyler, who has served as vice chairman and as an independent director, has been appointed chairman.

16:28 EDT NuStar Energy chairman Greehey acquires 110,299 common units - In a regulatory filing, NuStar Energy chairman William Greehey disclosed the purchase of 110,299 common units of the company on August 18 at a price of $15.8141 per share.

16:18 EDT Blackbaud acquires Kilter engagement app - Blackbaud has acquired Kilter. The acquisition will allow Blackbaud to expand activity-based peer-to-peer fundraising engagement, and to support activity-based health and wellness initiatives for socially responsible companies. Kilter is an intuitive, gamified, activity-based engagement app boasting virtually limitless activity type choices. Blackbaud will leverage Kilter to support activity-based fundraising for Blackbaud TeamRaiser, an event-based fundraising software. In the future, Blackbaud also plans to extend Kilter's capabilities to YourCause CSRconnect customers, with integration to YourCause CSRconnect coming later in 2023. The app will be introduced to select customers in late 2022.

16:17 EDT Biocept discloses Deficiency Notice from Nasdaq on 10-Q filing - Biocept "announces that it received a notice on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising Biocept that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250 as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 in a timely manner. Under Nasdaq rules, Biocept has 60 calendar days from the receipt of the Notice, or until October 17, 2022, to submit a plan to regain compliance with the Rule. "

16:16 EDT Invacare announces cooperation agreement with Azurite Management - Invacare announced that it has entered into a cooperation agreement with its largest shareholder, Azurite Management LLC, which currently owns approximately 10.3% of the company's outstanding shares as of June 30, 2022. As part of the agreement, Invacare appointed two new independent directors, Steven H. Rosen and Ambassador Edward F. Crawford, effective immediately. Rosen will serve on the company's Audit and Compensation and Management Development Committees, and Ambassador Crawford will serve on the company's Nominating and Governance Committee. "Following constructive dialogue and collaboration with Azurite, we are pleased to strengthen our Board with the addition of Mr. Rosen and Ambassador Crawford. They bring a wealth of experience in operations and business transformation, and their familiarity with Invacare's history will be invaluable. We look forward to collaborating with them on ways to accelerate our business evolution and enhance profitability," said Matt Monaghan, chairman, president and chief executive officer. As a result of other business commitments, Julie A. Beck and Stephanie L. Fehr have resigned from the Board effective August 22, 2022. Monaghan commented, "I would like to thank Julie and Stephanie for their exemplary service to Invacare and wish them the best in their future endeavors." With the changes announced today, the number of Invacare directors remains at eight total members, seven of whom are independent. The company remains committed to appointing at least one director who is racially and/or ethnically diverse by the next annual meeting. Under the terms of the cooperation agreement between Invacare and Azurite, Azurite has agreed to customary standstill, voting and other provisions

16:13 EDT Flexsteel Industries CEO says market headwinds may pressure first half of FY23 - CEO Jerry Dittmer adds: "Given my confidence in our team's commitment to profitable growth, we enter fiscal 2023 well positioned to successfully face the challenges ahead while still delivering improved earnings and a stronger balance sheet. We are focused on inventory management and successfully reduced inventory levels by $19.9 million versus where we ended a year ago. We expect reductions in inventory to generate positive operating cash flow in the fiscal year 2023 as we continue to right-size our inventory levels. In summary, we're enthusiastic about the long-term growth opportunities for the Company while being mindful of the short-term challenges we will face ahead and are making the right strategic decisions now to realize our growth potential. While our long-term growth outlook remains promising, there are a few market headwinds which we are navigating in the short-term that may create pressure on our first half profit results for fiscal 2023. First, consumer demand is waning due to the slowing of the economy and demand normalization compared to the pandemic-induced spending of recent years. At the same time, retailers are receiving a significant amount of imported inventory, leading to an inventory glut at most retailers. These historically high levels of inventory may lead to aggressive pricing actions taken by competitors in order to continue to move inventory. Second, cost inflation remains a prominent risk. We realized major cost increases during the past fiscal year in virtually all our raw materials and finished goods as well as labor and domestic transportation. Continued imbalances between supply and demand for these resources may continue to exert upward pressure on costs. In response to all these factors, we continue to prudently manage discretionary SG&A expenditures, pursue new sources of profitable growth, and drive cost efficiencies to partially offset these margin pressures until cost increases and supply chain disruptions are alleviated. We believe the next twelve months will be challenging for our industry due to slowdowns in the economy and furniture demand, continued inflationary pressures, and bloated retailer inventory levels which will put pressure on our profit margins in the near term. However, I am confident that our team and the investments we made in fiscal 2022 will provide a solid foundation for long-term profitable growth. Production at our third and newest manufacturing plant in Juarez, Mexico accelerated the reduction of our backlog, sustaining our advantage service levels in the market. Our new distribution center in Greencastle, Pennsylvania is supporting improved service levels and growth on the East Coast. While these recent investments to expand North American capacity may be underutilized in the near term, they will support improved customer service levels, build supply chain resiliency and provide meaningful capacity for future growth. These initiatives combined with ongoing investments in talent, product innovation, digital capabilities, and our brands, position us well to compete effectively in the near term as well as achieve our longer-term growth ambitions."

16:11 EDT Palo Alto Networks CEO 'pleased' with Q4 results - "We were pleased by our fourth quarter results, which included GAAP profitability for the first time in four years. Next-Generation Security growth, driven by our rapid pace of innovation and strong sales execution, drove our results," said Nikesh Arora, chairman and CEO of Palo Alto Networks. "As cybersecurity posture remains critical, our integrated three-platform strategy continues to drive large deal momentum as we consolidate and simplify our customers' security architectures." "Our focus on maximizing total shareholder return in any environment was exhibited by strong revenue and billings growth, paired with non-GAAP operating margin and non-GAAP adjusted free cash flow margin expansion in fiscal year 2022," said Dipak Golechha, CFO of Palo Alto Networks. "As we enter fiscal year 2023, we look forward to again delivering this balance of growth and margin expansion, while also achieving GAAP profitability for the year."

16:09 EDT Palo Alto Networks board approves three-for-one stock split - Palo Alto Networks announced that the board of directors has approved and declared a three-for-one split of Palo Alto Networks' common stock in the form of a stock dividend. Each stockholder of record at the close of business on September 6 will receive, after the close of business on September 13, two additional shares for every share held on the record date, and trading will begin on a split-adjusted basis on September 14.

16:07 EDT Opiant Pharmaceuticals announces notice of allowance from USPTO - Opiant Pharmaceuticals announced that the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for Opiant's pipeline candidate OPNT004 for the treatment of cannabinoid hyperemesis syndrome, a condition among cannabis users that leads to repeated and severe bouts of vomiting. A Notice of Allowance is issued after the USPTO decides that a patent can be granted from an application. The USPTO issued a Notice of Allowance for U.S. Patent Application 16/904,359, entitled "Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist" for OPNT004. This patent covers OPNT004 as a method of treatment for CHS using drinabant administered as a parenteral formulation. Opiant expects this patent to issue within the next few months and expire no earlier than 2040.

16:01 EDT Edgio names Stephen Cumming CFO, Rich Diegman CLO - Edgio announced the appointment of Stephen Cumming as chief financial officer and Rich Diegnan as chief legal officer. "We are excited to have Stephen and Rich join us. Their proven operational and strategic leadership will help us continue building positive momentum," said Bob Lyons, Edgio CEO. Stephen Cumming joins Edgio from network infrastructure company, Cambium Networks, where he was the CFO and took the company public in 2019. Before Cambium, Stephen was the CFO at privately-held SaaS company, Kenandy, which was successfully sold to Rootstock. Prior to that, Stephen held senior leadership positions as CFO at Atmel Corporation and Fairchild Semiconductor where he helped drive growth and profitability improvements both domestically and internationally.

14:07 EDT Revlon falls 11% to $7.56 after WSJ report on court filing

14:02 EDT Value Line trading resumes

13:38 EDT WeTrade Group Inc trading resumes

12:18 EDT Vail Resorts to limit lift tickets throughout 2022/2023 season - Vail Resorts announced the opening dates of its 37 North American resorts and shared that it will limit lift ticket sales throughout the entirety of the 2022/2023 season "to prioritize the mountain experience for its guests." James O'Donnell, president of Vail Resorts' Mountain division, said, "Limiting lift tickets throughout the season, alongside the big investments we're making at our resorts and in our team members, will help us provide our guests with an Experience of a Lifetime this winter." Guests can also expect "more normal indoor operations this season as dining facilities will no longer require proof of COVID-19 vaccinations or dining reservations," Vail added.

12:00 EDT Carvana falls -11.2% - Carvana is down -11.2%, or -$4.73 to $37.57.

12:00 EDT Blue Apron rises 9.5% - Blue Apron is up 9.5%, or 46c to $5.32.

12:00 EDT Signify Health rises 33.8% - Signify Health is up 33.8%, or $7.16 to $28.36.

11:47 EDT Enact Holdings appoints Neenu Kainth as chief customer experience officer - Enact Holdings announced Neenu Kainth as the company's new Chief Customer Experience Officer. Kainth most recently served as EVP Chief Digital Officer at Newrez.

11:15 EDT CDC recommends Novavax COVID vaccine for ages 12 to 17 - Centers for Disease Control and Prevention Director Rochelle Walensky signed a decision memo that Novavax's COVID-19 vaccine be used as another primary series option for adolescents ages 12 through 17. The recommendation follows FDA's authorization to authorize the vaccine for this age group under emergency use. "Novavax's COVID-19 vaccine, which is available now, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents. Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers," the CDC said in a statement. Reference Link

10:50 EDT CHW Acquisition Corp trading halted, volatility trading pause

10:34 EDT Pfizer, BioNTech submit appliation to FDA for Omicron vaccine - Pfizer (PFE) and BioNTech (BNTX) announced they have completed a submission to the Food and Drug Administration requesting Emergency Use Authorization of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. The application follows guidance from the FDA to include clinical data from the companies' bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies' bivalent Omicron BA.4/BA.5-adapted vaccine to address the continued evolution of SARS-CoV-2. Pending authorization, the Omicron BA.4/BA.5-adapted bivalent vaccine will be available to ship immediately, they said in a statement. A conditional marketing authorization application has also been initiated with the European Medicines Agency for the Omicron BA.4/BA.5-adapted bivalent vaccine and is expected to be completed in the coming days, the companies added.

10:19 EDT GNC deepens partnership with Honest Company - NC announced that is has deepened its partnership with The Honest Companythrough an exclusive retail partnership launching four new products available only at GNC and The Honest Company beginning in August. The products include: Nightly Sleep Health: Featuring a proprietary blend of active ingredients including theanine and valerian to help calm the mind and support healthy sleep. Daily Mood Balance: Featuring a proprietary blend containing rhodiola and phosphatidylcholine to help manage everyday stress and a balanced mood. Daily Immune Support: Featuring a powerhouse blend of zinc, vitamin D and organic green propolis, to support everyday immune health. Postnatal Hair Wellness: Formulated with clinically tested keranat oil to help maintain hair and scalp health.

10:02 EDT Kinderhook acquires Tank and Pump form WillScot Mobile Mini for $323M - Kinderhook Industries announced the execution of a definitive agreement pursuant to which it will acquire 100% of the equity interests of Gulf Tanks Holdings from WillScot Mobile Mini Holdings for an enterprise value of approximately $323 million. The transaction is subject to customary closing conditions and regulatory approval and is expected to close in the third quarter of 2022. This acquisition represents Kinderhook's 79th environmental / business services transaction and 17th public company carve out since inception. Headquartered in Baytown, Texas, Tank and Pump is a leading provider of logistics based environmental solutions focused on the containment of liquid and solid industrial waste. The Company provides environmental solutions across a diverse set of end markets through a network of 24 branches and a young fleet of over 16,000 specialized rental assets used to store, separate, and transport liquid and solid industrial waste. Tank and Pump's best in class service and prioritization of compliance through its proprietary technology platform, EnviroTrack, makes them the first choice for waste generators. The current leadership team of Tank and Pump will continue on with the new platform. Eric John, Senior Vice President of the Tank and Pump segment, will serve as the Chief Executive Officer of the newly established Tank and Pump platform post-closing.

10:00 EDT System1 falls -8.1% - System1 is down -8.1%, or -82c to $9.30.

10:00 EDT Weber falls -12.3% - Weber is down -12.3%, or -$1.09 to $7.76.

10:00 EDT AMC Entertainment rises 31.0% - AMC Entertainment is up 31.0%, or $2.79 to $11.80.

10:00 EDT Signify Health rises 39.2% - Signify Health is up 39.2%, or $8.30 to $29.50.

09:47 EDT Vince Holding falls -8.1% - Vince Holding is down -8.1%, or -62c to $7.00.

09:47 EDT Weber falls -10.5% - Weber is down -10.5%, or -93c to $7.92.

09:47 EDT AMC Entertainment rises 23.3% - AMC Entertainment is up 23.3%, or $2.10 to $11.11.

09:46 EDT AMC Entertainment trading resumes

09:40 EDT AMC Entertainment trading halted, volatility trading pause

09:38 EDT Valens to resume trading at 10:00am ET

09:36 EDT Golden Sun Education Group Ltd trading resumes

09:35 EDT SNDL to acquire The Valens Company in C$138M transaction - SNDL Inc. (SNDL) and The Valens Company (VLNS) are pleased to announce that they have entered into an arrangement agreement to combine their businesses and create a leading vertically integrated cannabis platform. Pursuant to the terms of the Agreement, SNDL will acquire all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement Under the terms of the Agreement, Valens' shareholders will receive, for each Valens Share, 0.3334 of a common share of SNDL. Based on the August 19, 2022 close of the SNDL shares on the Nasdaq Capital Market exchange, the consideration represents an implied value of $1.26 per Valens Share, for total consideration of approximately $138 million. The Implied Offer Price represents a premium of 10% based on a trailing 30-day volume-weighted average price of the Valens Shares, on the Toronto Stock Exchange up to August 19, 2022. With 555,500 square feet of cultivation and manufacturing space and 185 cannabis stores under the Spiritleaf and Value Buds banners, the combined company will offer a complete portfolio of branded products to consumers in Canada through its own supply and distribution channels. With approximately $314 million in net cash and no debt, SNDL will continue to have one of the strongest balance sheets in the North American regulated cannabis industry. SNDL will also have the highest pro forma Canadian cannabis revenue on a last fiscal quarter annualized basis. The combined company will operate as SNDL Inc., and Valens shareholders will own approximately 9.5% of the pro forma entity. Synergies through cost rationalization and operational efficiencies: The combination of SNDL and Valens is expected to deliver more than $10 million of annual cost synergies. Together with incremental revenues from greater distribution of Valens products, it is estimated that the Transaction will deliver upwards of $15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives. Valens' secured non-revolving term loan has been refinanced and upsized with an additional $14.3 million of incremental capital, thereby increasing the principal amount of the Term Loan to $60 million. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act, pursuant to which SNDL will acquire all of the issued and outstanding Valens Shares, other than those owned by SNDL and its subsidiaries. The implementation of the Transaction will be subject to the approval of at least two thirds of the Valens Shares entitled to be voted by Valens shareholders and the approval of a simple majority of the Valens Shares entitled to be voted by Valens shareholders, other than Valens shareholders required to be excluded under applicable laws, at a special meeting expected to be convened by Valens by the end of November 2022 (the "Meeting"), and the receipt of applicable orders from the Ontario Superior Court of Justice and applicable regulatory approvals, including under the Competition Act and the applicable provincial liquor and cannabis regulators. The Agreement provides for, among other things, customary support and non-solicitation covenants from Valens, including customary "fiduciary out" provisions that allow Valens to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of SNDL. The Agreement also provides for the payment of a termination fee of $8 million payable to SNDL by Valens in the event the Transaction is terminated in certain specified circumstances. The transaction is expected to close during January 2023. All directors and executive officers of Valens have entered into voting support agreements with SNDL pursuant to which, among other things, the parties have agreed to vote their Valens Shares in favour of the Transaction. Valens' board of directors has unanimously approved the Transaction after receiving the unanimous recommendation of a special committee of Valens directors. Valens' board of directors has unanimously resolved to recommend that the shareholders of Valens vote in favour of the Transaction.

09:32 EDT Inpixon Swarm Chirp V3 granted FCC, ISED certifications - Inpixon announced that its Inpixon Swarm Chirp V3 RF transceiver module received a Grant of Equipment Authorization certification from the U.S. Federal Communications Commission and a certificate from ISED Canada. The company also signed a CE declaration of conformity confirming the product passed RED, EMC and LVD tests.

09:30 EDT Graphex Group highlights U.S. expansion progress - Graphex Technologies provided an update that reflects on milestones achieved in 2022 and its objectives for the remainder of the year. The expansion of Graphex Technologies' presence in the U.S. - and more specifically in Warren, MI, the heart of the automotive sector - comes at a critical moment in global transportation history as evidenced by the recent enactment of the Inflation Reduction Act of 2022, which is slated to provide the largest investment to combat climate change in U.S. history. As the demand projections for electric vehicles and other sustainable energy solutions are expected to grow, there will be a parallel increase in demand for the critical minerals necessary to manufacture the Li-ion batteries that power them. Equally as important, the tremendous impetus for the industry to move supply chains away from geopolitically sensitive or logistically challenging regions and to localize end-to-end processing and production capabilities in the U.S. is at the highest intensity in decades. Graphex is currently among the top suppliers of specialized spherical graphite to the EV and renewable energy industries with a global expansion strategy that completely supports energy transition and electrification efforts worldwide. Recent milestones and actions to achieve our business objectives include: Graphex is one of the largest specialized graphite processors in the world: Increasing production from 10,000 to 40,000 tonnes per annum to meet growing EV demand; Diversifying upstream sourcing of raw materials to stabilize supply chains: Actively negotiating offtake agreements with sources of natural graphite away from politically sensitive and/or logistically volatile regions; Pursuing new raw material sources around the world including the US, Brazil, Canada, Africa, Australia, Europe, and other locations through a combination of straight offtake agreements for raw materials and also through collaborative partnerships with the mining operations to construct mid-stream processing facilities near the raw material sources. Building mid-stream processing plants in North America: The previously announced joint venture with Emerald Energy Solutions LLC to construct a new 15,000 metric ton per year graphite processing facility in Warren, Michigan is progressing as planned. The first such plant to be built by an experienced commercial- scale mid-stream graphite processor in the US and the first of multiple facilities anticipated by Graphex, the Warren facility is expected to be operational in Q2/Q3 of 2023. Actively negotiating supply agreements to sell product to the battery manufacturers in the West: Graphex has entered into at least one confidential non-binding MOU with OEM EV battery manufacturers to supply anode material to their future gigafactories, including one in the US, and to evaluate the construction of co-located processing facilities near the OEM's gigafactories. Graphex is engaged in similar ongoing discussions with other OEMs and battery manufacturers. Continuing our research of advanced battery chemistry and material science innovations: Collaboration with the Technology Institute to conduct an in-depth Study on Electrode Materials for Graphene-based Sodium Ion Batteries

09:21 EDT eBay to acquire TCGplayer for up to $295M - eBay and TCGplayer, a trusted marketplace for collectible card game enthusiasts, announced they have entered into an agreement for eBay to acquire TCGplayer. Trading cards are an attractive category, which has seen substantial growth. TCGplayer is a leading technology platform for the collectibles industry, and will continue to operate autonomously as one of the largest online marketplaces for trading card games. This acquisition complements eBay's focus category strategy and furthers the company's commitment to trading card enthusiasts - providing eBay with strategic omnichannel capabilities like order fulfillment and cart optimization, maintaining its position as a desirable platform for trading card sellers, and enhancing the overall experience for all customers. eBay will acquire TCGplayer for a total deal value of up to approximately $295M. The deal is subject to customary closing conditions, including requisite regulatory approvals, and is expected to close in Q1 2023.

09:19 EDT Pinduoduo launches vertical farming challenge - Pinduoduo launched a vertical farming challenge for its 3rd Smart Agriculture Competition, an annual precision farming contest aimed at encouraging data scientists and agricultural researchers to develop productivity-boosting agricultural technology. A vertical farm is a farm in which crops are grown in trays stacked on top of each other, allowing cultivation at higher density. Globally, vertical farms have gained popularity for their ability to produce higher yields by controlling light, temperature and nutrients, while minimizing disease, infestation, and pollution. Participating teams in the Pinduoduo Smart Agriculture Competition will compete to produce lettuce in shipping containers, using technology including LED lighting, crop modeling, and algorithms to control input variables. They will take on the challenge of producing crops with higher yields and better quality using shorter growth cycles and less energy. Besides productivity and sustainability, the judging panel will also take into consideration the commercial viability of the different teams' growing models.

09:15 EDT QuisLex partners with eBrevia by DFIN to offer CLM migration solution - QuisLex and eBrevia by DFIN announce a strategic partnership designed to provide seamless contract life cycle management migration. The combined solution helps to alleviate the difficulties of CLM migration while ensuring an efficient and highly accurate process. QuisLex and eBrevia are exhibiting at ILTACON 2022, where they will highlight the benefits of this partnership. QuisLex contract services include review, analysis, abstraction, negotiation and life cycle management across multiple agreement types and industries. For corporations adopting a new CLM, without an automated tool the process of migrating documents from an existing system can be onerous and time-consuming. The exercise often involves evaluating which company contracts should be carried over onto the new platform and addressing any holes in the contract data collected by the current repository. The QuisLex and eBrevia combined solution addresses the many challenges inherent in the CLM migration process. eBrevia by DFIN provides industry-leading AI-powered contract analytics software that speeds up contract review by 30-90% with a 10-60% increase in accuracy. Part of DFIN's suite of solutions, eBrevia is ideal for large-scale contract review projects with applications ranging from due diligence in M&A transactions to audit/compliance work.

09:09 EDT Volcon prices $27.2M convertible senior notes offering - Volcon announced it has signed a securities purchase agreement on August 22, 2022 to issue to an investor $27.2 million aggregate principal amount of convertible senior notes due 2024 and accompanying warrants to purchase approximately 9.1 million shares of common stock. The Notes will be senior unsecured obligations of Volcon and no interest shall accrue unless and until an event of default has occurred. Each of the Notes shall include an original issue discount of 8.0%. The Notes will mature on February 24, 2024 unless earlier converted. The initial conversion price will be $2.25 per share of common stock, subject to adjustment upon the occurrence of specified events. The Warrants will be exercisable immediately upon the date of issuance and have an initial exercise price of $2.85. The Warrants will expire five years from the date of issuance. The sale of the Notes is expected to close on August 24, 2022, subject to customary closing conditions.

09:09 EDT Alpha Cognition announces results from bioequivalence study with ALPHA-1062 - Alpha Cognition announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer's Disease, AD. The company elected to conduct this additional study which was designed to demonstrate pharmacokinetic equivalence between 5mg ALPHA-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release capsules. These data, coupled with the positive pivotal data released in June, establish bioequivalence to both formulations of galantamine hydrobromide and strengthen the NDA application for ALPHA-1062 in mild-to-moderate AD, planned for Q2 2023. The study was a two-treatment, two-period, crossover study wherein 40 subjects were randomly assigned 1:1 to either treatment with ALPHA-1062 5mg twice daily, or galantamine hydrobromide 8mg ER capsules once daily, for 7 days. After a one-week washout period, subjects were then crossed over to the other treatment arm and dosed for 7 days. Topline results confirmed that in healthy adult volunteers treated to steady state, ALPHA-1062 was bioequivalent to galantamine hydrobromide ER. In the pre-specified primary analysis, ALPHA-1062 achieved area-under-the-curve and peak exposures of approximately 107% and 127%, respectively, compared to those generated by galantamine hydrobromide ER.

09:08 EDT Lifeist's Mikra Cellular launches advertising campaign - Lifeist Wellnes announced that its wholly owned U.S. subsidiary Mikra Cellular Sciences has secured significant premium media inventory across the Disney Hulu XP advertising network, which includes Hulu, ESPN, and other Disney properties. The broader advertising campaign will launch on August 29.

09:07 EDT Alpha Tau MIM team for Alpha DaRT therapy - Alpha Tau Medical and MIM Software announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy. Under the terms of the agreement, the parties will collaborate on the use of MIM's software suite, including MIM Symphony and MIMcloud , for development of new features and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIM's software are both approved. The MIM Symphony treatment planning software guides clinicians through an easy step-by-step process to place Alpha DaRT sources precisely and create a patient-personalized treatment plan. MIM's proprietary image manipulation capabilities, including MIM ReSlicer, and process and data management with MIM Workflows and MIMcloud, allow MIM Symphony to support treatment planning flexibly across multiple disease sites. Versatile guidance capabilities, including the ability to create custom 3D-printed access devices, assist in Alpha DaRT placement for challenging targets.

09:06 EDT E-Home Household expects to report over 3M registered members as of June 30 - E-Home Household Service Holdings announced unaudited preliminary operation matric for fiscal year ended June 30, 2022 as the Company's business performance is picking up quickly amid China's endeavor to resume normal operation of businesses operating in different sectors. The company is expected to achieve a significant increase in revenue and positive net profit growth for the fiscal year ending June 30, 2022. E-Home is anticipated to report more than 3 million registered members as of June 30, 2022, with over 2 million members using the Company's services during the same reporting period. In total the Company is expected to receive more than 1 million orders, among which over 500,000 orders coming from installation and maintenance services, nearly 700,000 orders are housekeeping and over 50,000 orders coming from senior care services for the fiscal year ended June 30, 2022. Wenshan Xie, Chairman and CEO of E-Home, commented: "Despite the Covid-19 resurgence and macro uncertainties for the past year, we quickly adjust our business strategies and introduced a number of new initiatives including metaverse and monkeypox treatment initiatives that have helped the Company explore and diversify streams of revenues. The Company is also expected to announce a resilient set of results as we maintain high quality services and capitalize on the recovered momentum by leveraging our strong infrastructure and capacity advantages. While Covid-19 did impact on our business performance and short-term challenges still exist in the marketplace, the household services industry is resilient with huge potential to expand. We will devote fully to executing our strategies to widen market share lead and enhance operational excellence in the near future, which should be crucial for consistent and profitable growth."

09:05 EDT Sage Group appoints Mark Hickman as MD, Sage Canada - Sage has named Mark Hickman as the new Managing Director for Sage Canada, effective August 2, 2022. In this role, Mark will lead the evolution of Sage in Canada and help guide the company's growth over the next several years. Hickman has worked in a leadership capacity at APOLLO, Calligo, Tyler Technologies and WinMagic, where he consistently grew revenues and led teams in North America and globally.

09:04 EDT AMD issues annual Corporate Responsibility Report - AMD announced its 27th annual Corporate Responsibility Report, demonstrating how AMD - together with its employees, customers, partners, and communities - advances computing to help solve the world's most important social and environmental challenges. From advancing sustainable computing to cultivating a diverse workforce, AMD is committed to responsibly delivering on its mission to be the high-performance and adaptive computing leader. AMD now powers the fastest and most energy-efficient supercomputer in the world - the Frontier supercomputer - as well as 17 of the top 20 most efficient supercomputers. To drive continued innovation, diversity hiring remains a component of the company's strategic metrics and milestones to inform its annual bonus program. AMD also entered into a $3 billion sustainability-linked credit facility, demonstrating its commitment to advancing sustainability. In 2021, AMD announced new corporate responsibility goals for 2025 and 2030 spanning digital impact, environmental sustainability, supply chain responsibility, and diversity, belonging, and inclusion. Today, the company reported it is on track to achieve these goals.

09:03 EDT Direct Digital appoints Maria Vilchez as Chief Growth Officer - Direct Digital Holdings (DRCT) announced that Maria Vilchez Lowrey has joined as Chief Growth Officer. In this newly created role, reporting to Chairman and CEO Mark Walker as a member of Direct Digital Holdings' leadership team, Vilchez Lowrey is responsible for leading business development, channel development, and integrating the management of brand related activities across Direct Digital Holdings' portfolio of brands. Additionally, her appointment marks the professional reunion of Vilchez Lowrey with CEO Walker: they worked together earlier in their careers at NRG Energy (NRG), a leading Fortune 300 integrated power company. Vilchez Lowrey is an experienced sales leader with a proven 20-year record in creating business-to-consumer and business-to-business sales capabilities at scale within the Fortune 500. Vilchez Lowrey comes to Direct Digital Holdings from Just Energy, where she served as Senior Vice President of Direct Sales and Partnerships for Just Energy, Amigo Energy, Tara Energy, and Terrapass, its affiliate brands. There, she was responsible for diversifying the company's direct sales channels by launching its first national retail partnership with one of the largest retailers in the world.

09:02 EDT Fatburger, Buffalo's Express opens in Marrakesh - FAT Brands announces the opening of the first Fatburger and Buffalo's Express in Morocco. Located in Marrakesh on the famous M Avenue, the co-branded restaurant provides premium American fare, including delicious, custom-built burgers and award-winning wings.

08:50 EDT Lumen receives FFC approval to sell ILEC business to Brightspeed - The Federal Communications Commission, or FCC, has approved the previously announced sale of Lumen Technologies' (LUMN) incumbent local exchange carrier, or ILEC, business in 20 states to Brightspeed. With this approval, the transaction has now received all final regulatory clearances needed to close. Pending other customary closing conditions, the transaction with Apollo-managed funds (APO) is expected to close early in the Q4. Brightspeed plans to make significant investments to build an expanded fiber optics network that will bring fast, reliable internet and Wi-Fi to communities throughout the 20-state footprint it is acquiring. These plans include providing fiber facilities that are expected to reach up to three million homes and businesses over the next five years, including in many rural and suburban locations where fiber and advanced technology have not yet been deployed.

08:47 EDT ABVC BioPharma to initiate Phase II clinical trials for ABV-1703 in 2Q23 - ABVC BioPharma provided an update on its development of oncology medicines for the treatment pancreatic cancer , non-small cell lung cancer triple negative breast cancer and myelodysplastic syndrome. The Company expects to initiate the first Phase II clinical trials for ABV-1703 in the second quarter of 2023 by Dr. Andrew E. Hendifar at the Cedars-Sinai Medical Center in Los Angeles, California.Early Studies of the Maitake Mushroom The medicines developed by ABVC for oncology disorders are based on research conducted in Asia over the past 25 years, as well as a Phase I/II dose escalation trial performed in 2017 at the Memorial Sloan Kettering Cancer Center in New York to determine the therapeutic effects of an ingredient derived from the Maitake mushroom.

08:44 EDT American Resources expands non-dilutive credit facility - American Resources Corporation announced that it, along with its wholly-owned subsidiary American Carbon LLC, has expanded a non-dilutive, traditional asset backed credit line of $15 million that can be drawn against for growth initiatives. The expanded credit facility, with the Company's existing lender Maxus Capital Group, is a traditional equipment loan secured by certain equipment of the Company American Carbon division. The equipment loan allows the Company to draw up to $15 million and carries a 36-month term. Based on a full lease facility advance, it is anticipated the equipment loan will bear an effective initial interest rate of approximately 14.48% over the term of the loan. Furthermore, with separate financing facilities at both the ReElement Technologies and American Carbon subsidiaries, American Resources has further financial flexibility to execute on select value creation initiatives that the Company's recently announced special committee believes are beneficial.

08:44 EDT VLNS Stock trading halted, news pending

08:42 EDT DatChat to homestead Habytat metaverse - DatChat through its SmarterVerse announced it will homestead the Habytat metaverse. The Company will grant land parcels and homes based on its proprietary Dynamic Content NFT technology to qualified applicants. After achieving a predetermined level of active participation, the property will be deeded to the participant. As recipients of land parcels interact with their property, the more it can continue to grow, improve, and evolve. Additionally, the Habytat metaverse will be based on an advertising-based revenue model and will offer rewards and additional incentives for active participants. Residential parcels for Geniuz City, the first world of The Habytat metaverse, are now open for pre-registration.

08:39 EDT Salarius adds two Mayo Clinic sites for seclidemstat study on sarcoma treatment - Salarius Pharmaceuticals announces the addition of the Mayo Clinic to its open-label Phase 1/2 trial with seclidemstat in Ewing's sarcoma and FET-rearranged sarcomas. Mayo Clinic locations in Rochester, Minnesota, and Jacksonville, Florida are now supporting trial enrollment. Seclidemstat is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression. The Mayo Clinic site in Rochester is being led by Scott H. Okuno, M.D., Chair of the Division of Community Oncology for the Department of Oncology and Chair of the Mayo Clinic Health System Cancer Committee, and the Mayo Clinic site in Jacksonville is being led by Steven Attia, D.O. of the Mayo Clinic Comprehensive Cancer Center. David Arthur, chief executive officer of Salarius, said, "Ewing's sarcoma and FET-rearranged sarcomas are particularly motivating for us, given the pediatric patient population effected by these diseases, and we believe that seclidemstat could play an important role as a potential treatment for these sarcomas. The addition of these prestigious Mayo Clinic sites to our list of trial sites is deeply gratifying and we are grateful to have Dr.'s Okuno and Attia joining our roster of notable investigators leading the sarcoma study across the U.S."

08:39 EDT ETFMG's MJ cannabis ETF to include multi-state operators - ETF Mangers Group announced that ETFMG Alternative Harvest ETF, the world's first cannabis ETF, will complete its global portfolio by offering exposure to cannabis companies operating in the United States which include multi-state operators directly involved in the cultivation, production, marketing and distribution of cannabis or cannabis-related products. "We are excited to offer our investors exposure to the global cannabis industry through MJ, the world's largest global cannabis fund. ETFMG is proud to be the one-stop shop for those interested in investing in cannabis with a suite featuring 2X long, 2X short, US - only or global exposure," said ETFMG CEO and Founder, Sam Masucci.

08:38 EDT WillScot Mobile to divest Tank and Pump segment to Kinderhook for $323M - WillScot Mobile Mini Holdings announced a definitive agreement, whereby the Company will divest its Tank and Pump segment to private equity firm Kinderhook Industries for an enterprise value of approximately $323 million, subject to customary post-closing adjustments. Proceeds from the sale will be used to support ongoing reinvestment in the Company's core Modular and Storage operating segments and other capital allocation priorities. The transaction is subject to customary closing conditions and regulatory approval and is expected to close in the third quarter of 2022. Eric John, Senior Vice President of the Tank and Pump segment, will serve as the CEO of the newly independent business.

08:37 EDT TFI International to sell CFI's truckload business to Heartland for $525M - TFI International (TFII) has signed a definitive agreement to sell CFI's Truckload, Temp Control and Mexican non-asset logistics businesses to Heartland Express (HTLD) for $525 million, subject to certain agreed upon adjustments. The transaction is subject to the satisfaction or waiver of usual and customary closing conditions, including regulatory approvals. The CFI TL, TC & MX Business currently operates primarily in the US-based Conventional TL operating segment of TFI's Truckload segment and provides comprehensive truckload service offerings, including time definite dry-van truckload, long-haul and short-haul freight transportation, reefer transportation and Mexico-based non-asset logistics services. The CFI TL, TC & MX Business has ~2,000 tractors, ~7,800 trailers and ~2,800 employees. CFI's Mexican logistics business has a network of nearly 200 C-TPAT certified Mexico carrier partners. TFI is keeping the Dedicated and US Logistics divisions. The CFI TL, TC & MX Business generated approximately US$450 million in revenue before fuel surcharge and operating income of approximately US$50 million in 2021. Pro forma for the transaction, TFI expects its FY 2022 EPS guidance of US$8.00 to remain unchanged, and pro forma funded debt-to-EBITDA ratio to decline to approximately 1.0x from approximately 1.3x as of June 30, 2022. The CFI TL, TC & MX Business is the most capital intensive in the TFI portfolio. TFI will retain its Dedicated and US Logistics businesses. For the Dedicated business, revenue and operating income for the trailing 12-month period ended June 30, 2022 was ~US$401 million and ~US$21 million, respectively. For the US Logistics business, revenue and operating income for the trailing 12-month period ended June 30, 2022 was ~US$146 million and ~US$11 million, respectively. The transaction has been unanimously approved by the boards of both TFI and Heartland and is expected to close in the third quarter of 2022 subject to the satisfaction or waiver of usual and customary closing conditions, including regulatory approvals.

08:36 EDT IAA announces launch of CARFAX Canada vehicle history reports - IAA announces that non-branded, repairable IAA vehicles in Canada now include CARFAX Canada Vehicle History Reports. IAA's Vehicle Details Page within the Auction Centre will now provide the most comprehensive vehicle history report available in Canada. This launch will allow buyers to fully view any available vehicle history report - with no limits or restrictions - paying only when they purchase the vehicle. "CARFAX Canada maintains a strong, established reputation in the industry and we are proud to work with them to improve buyer confidence in the integrity of IAA and the vehicles we sell," said Blair Earle, Managing Director, Canada for IAA. "This CARFAX Canada integration will ensure our buyers understand more about a vehicle's history, enabling them to make more-informed buying decisions and improving the overall buyer experience."

08:36 EDT Enfusion appoints Movchan interim CEO - Enfusion announced that its Board of Directors has appointed Oleg Movchan, currently a member of the Board, as Interim Chief Executive Officer, CEO, effective August 21, 2022. Movchan succeeds Thomas Kim, who has resigned as CEO and as a Director of the Company so that he can spend more time with his family. Movchan has been an Enfusion investor and a Board member for over 10 years, and has worked closely with the Company's management team as Enfusion developed its leading cloud-based investment management software and services. The Board has retained an executive search firm to assist with the search process for the permanent Chief Executive Officer role.

08:33 EDT Chicken Soup for the Soul Entertainment announce senior leadership team - Chicken Soup for the Soul Entertainment's chairman and chief executive officer, William Rouhana announced the formation of a new senior leadership team drawn from both Chicken Soup for the Soul Entertainment and Redbox. As previously announced, entertainment and streaming industry veterans Galen C. Smith, executive vice chairman, and Jonathan Katz, president, will lead this team of executives across a number of areas to support the company's rapid growth. Both Smith and Katz will report to Rouhana. The Chicken Soup for the Soul Entertainment leadership team will consist of: Galen Smith, executive vice chairman of Redbox and Chicken Soup for the Soul Entertainment, will oversee all long-term planning for the company, including strategy, mergers and acquisitions, and corporate services. Reporting to him: Senior Vice President Corporate Communications, Peter Binazeski - Heads the company's corporate communications and public relations; Chief People Officer, Marisa Famulare - Continues to direct all people functions; Chief Innovation Officer, Jason Kwong - Shifts duties to newly expanded role incubating and developing future areas of growth for the combined business; Chief Financial Officer, Chris Mitchell - Continues responsibility for all financial operations, capital structure, and investor relations; Chief Strategy Officer, Elana Sofko - Continues to manage M&A activities and international expansion; and Chief Legal Officer, Fred Stein - Expands his Redbox role to oversee all legal, business affairs and risk management. Jonathan Katz, president, will oversee day-to-day operations, including the company's streaming, kiosk, distribution, and studio businesses. Reporting to him: Chief Operating Officer and President, Redbox Service, Michael Chamberlain - Continues to oversee the operations of the Redbox kiosk business, and leads the growing kiosk service business; Chief Executive Officer, Studios, David Ellender - Continues to lead the Chicken Soup for the Soul Television Group, developing and producing original content for all owned-and-operated platforms, now including Redbox kiosks and streaming, as well as third-party productions; Chief Acquisitions & Distribution Officer, David Fannon - Continues to oversee all domestic and international content acquisition and distribution, expanding his purview to include Redbox, and continues in his role as President of Screen Media Ventures; Chief Marketing Officer, Mike Feldner - Adds the combined company to his Redbox role, heading up all marketing, branding, and creative services, along with leading the company's analytics and insights team; Chief Revenue Officer, Philippe Guelton - Expands role to lead all advertising sales and operations, as well as revenue partnerships across the company; and Chief Digital Officer, Adam Mosam - Adds to his responsibilities oversight of the company's streaming businesses, including product, technology, and platform distribution.

08:29 EDT Cue Biopharma doses 1st patient in CUE-102 study for Wilms' Tumor cancer - Cue Biopharma announced that it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate from the CUE-100 series of interleukin 2 based biologics, as a monotherapy for the treatment of patients with Wilms' Tumor 1 -positive recurrent/metastatic cancers. The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers. "Initiating this Phase 1 clinical study of CUE-102 at a starting dose of 1mg/kg, a clinically active dose in our Phase 1 CUE-101 clinical trial for HPV+ head and neck cancer, is an important step forward in demonstrating the modularity of our Immuno-STAT( platform and the broader clinical potential of our CUE-100 series of biologics," said Dan Passeri, chief executive officer of Cue Biopharma. "We believe, given the preservation of the core molecular framework between CUE-102 and CUE-101 with the primary exception of the tumor-specific epitope, initiating the dose escalation trial at 1 mg/kg will result in reduced time and cost to evaluate tolerability at therapeutically active doses."

08:26 EDT Calix announces Mukherjee joined board of directors - Calix announced that Raj Mukherjee has joined its board of directors to provide guidance to the industry-leading cloud and software company. Mukherjee brings two decades of expertise in cloud software products that drive business growth. Raj currently serves as the executive vice president and general manager, small business and international, at Indeed.

08:25 EDT Fluence Energy announces contract with Cubico Sustainable Investments - Fluence Energy announced a contract with Cubico Sustainable Investments to optimize the performance of the 350 MW Solem I and II solar plants in El Llano, Mexico, using Fluence's Nispera asset performance management software. Fluence's Nispera APM software integrates asset data with intelligent machine learning models and visualization tools to help solar and wind plant owners uncover hidden performance issues, minimize downtime, and maximize energy production. Nispera will optimize operations and maintenance of the Solem I and II solar plants, which make up one of the largest solar projects in Latin America, with a focus on detecting possible budget deviations while proposing measures to improve performance and revenue to deliver more clean energy to the grid and the municipality of El Llano, Mexico.

08:22 EDT Enphase Energy, Meraki Solar expand adoption of IQ Microinverters - Enphase Energy announced that Meraki Solar is expanding the adoption of Enphase IQ Microinverters as United States homeowners are hit with rising energy prices. Meraki Solar is headquartered in Florida and services customers in eight states across the country.

08:20 EDT Enlivex Therapeutics expects cash to fund operations through 3Q24 - As of June 30, 2022, Enlivex had cash, cash equivalents, and short-term deposits of $62.5 million. The Company believes its existing cash, cash equivalents, and short-term deposits will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2024.

08:17 EDT Minerva submits NDA to FDA for roluperidone - Minerva Neurosciences announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The roluperidone clinical development program aims to provide effective treatment for negative symptoms of schizophrenia, a significant unmet medical need in a large patient population.

08:14 EDT Arcutis Biotherapeutics announces Arcutis Cares is open for enrollment - Arcutis Biotherapeutics announced that Arcutis Cares, the first ever patient assistance program for a topical psoriasis product, is open for enrollment. Financially eligible individuals who are uninsured or underinsured may apply for the program to receive ZORYVE cream 0.3% at no cost. Arcutis Cares is open for application to individuals who meet certain financial eligibility requirements, are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford their medication. Covered individuals must be 12 years or older, a resident of the United States, and prescribed ZORYVE for an FDA-approved use. The application and the complete terms of the program are available by calling Arcutis Cares at 855-600-3755, or by visiting and downloading the form at arcutiscares.com and faxing to 855-237-9113. Terms and conditions are subject to change at any time. Individuals with commercial drug insurance may be eligible for the ZORYVE Direct Savings Card. Individuals may pay as little as $25 if their commercial drug insurance covers ZORYVE, and $75 if their commercial drug insurance currently does not cover ZORYVE.

08:09 EDT Baudax Bio receives notice of allowance for patent covering use of ANJESO - Baudax Bio announced that the United States Patent and Trademark Office has provided a Notice of Allowance for patent application No. 16/297,095, titled "Methods of administering intravenous meloxicam in a bolus dose", which includes claims covering the use of multiple doses of ANJESO for the treatment of moderate to severe pain resulting in a reduction in summed pain intensity difference and also a reduction in the use of rescue analgesia 48 hours following the first dose. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is expected to be issued in the coming months. Once issued, the '095 Application will be eligible for listing in the United States Food and Drug Administration's Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations as it relates to ANJESO. Once issued, the '095 Application will be the second ANJESO patent to be listed in the Orange Book with an expiry date of March 2039. Upon issuance, the '095 application will join seven other patents listed in the Orange Book, amongst others owned or licensed by Baudax that currently provide exclusivity to the ANJESO franchise. The '095 Application emphasizes ANJESO's potential to treat moderate to severe pain while potentially reducing the use of rescue analgesics.

08:07 EDT Aemetis to supply Aer Lingus, British Airways with SAF - Aemetis announced that it has agreed to a multi-year agreement with International Airlines Group to supply sustainable aviation fuel to help power both British Airways and Irish flag carrier Aer Lingus' flights from San Francisco Airport from 2025. IAG, parent company of both British Airways and Aer Lingus, will purchase a total of 78,400 tonnes1 of SAF over seven years, enough to reduce CO2 emissions by up to 248,000 tonnes across the same time period.

08:06 EDT ViaSat awarded $99M order from U.S. NAVWAR - Viasat announced it was awarded a $99M order for Multifunctional Information Distribution System, or MIDS, Joint Tactical Radio System, or JTRS, terminals from U.S. Naval Information Warfare Systems Command, or NAVWAR, on behalf of the MIDS Program Office. This order falls under a U.S. Navy Indefinite Delivery, Indefinite Quantity, or IDIQ, contract awarded to Viasat in 2020 with a maximum value of $998 million for the production, retrofits, development and sustainment of MIDS JTRS terminals. This order was received during Viasat's Q2 FY23.

08:04 EDT ALJ Regional Holdings announces voluntary delisting from NASDAQ - ALJ Regional Holdings announced that it has submitted a formal notice to Nasdaq Stock Market of its decision to voluntarily delist its common stock from the NASDAQ Global Market and its intent to file a Form 25 with the SEC on or about September 1. As a result, ALJ expects that the last day of trading of its common stock on the NASDAQ Global Market will be on or about September 11. After the Form 25 is effective, ALJ also intends to pursue such other measures necessary to terminate or suspend the registration of its common stock under the Securities Exchange Act of 1934, as amended. ALJ anticipates that its common stock will be quoted on the Pink Sheets platform, which is operated by OTC Markets Group, and ALJ currently intends to continue to provide information to its stockholders and to take such actions within its control to enable its common stock to be quoted in the Pink Sheets so that a trading market may continue to exist for its common stock. The Company expects the deregistration of its common stock to become effective 90 days after the date of filing the Form 25 with the SEC. However, its reporting obligations to file certain reports with the SEC, including Forms 10-Q, 10-K and 8-K, will be immediately suspended upon filing the Form 25. Other filing requirements will terminate upon effectiveness of the deregistration.

08:04 EDT GreenPower Motor appoints Leonard Bus Sales as a dealer for BEAST school bus - GreenPower Motor Company announced the appointment of Leonard Bus Sales as a dealer for GreenPower's BEAST Type D and Nano BEAST Type A all-electric school buses for the state of New York. Leonard has five locations and will have an exclusive appointment for the state of New York except for eight counties representing the New York City area, which will be non-exclusive. Leonard has initially agreed to purchase two BEAST and two Nano BEAST school buses from GreenPower for customers and demonstrations.

08:03 EDT Bath & Body Works launches nationwide loyalty program - Bath & Body Works celebrates the nationwide availability of its loyalty program, My Bath & Body Works Rewards. Customers ready to unlock a world of exclusive perks can enroll through the app, in stores or online. This program delivers value -- with just a $100 spend, customers receive a free product valued up to $16.50.

08:02 EDT Truist Financial acquires key strategic assets from Zaloni - Truist Financial announced that it has acquired key strategic assets from Zaloni, a data technology solution delivery company. Through this agreement, Truist will acquire the Zaloni Arena platform to accelerate its data governance, metadata management, advanced analytics, and artificial intelligence and machine learning programs. Zaloni Founder and Chief Product Officer Ben Sharma, Chief Technology Officer Ashwin Nayak, and a team of product, engineering and data professionals will join Truist's Enterprise Data Office led by Chief Data Officer Tracy Daniels. The team will be based in Raleigh.

08:01 EDT ProPetro Holding announces electric fleet orders, lease agreement - ProPetro announced it has executed a long-term lease agreement for two electric frac fleets with expected delivery in the third quarter of 2023. Sam Sledge, Chief Executive Officer, commented, "As part of our fleet transition strategy initiated last year, we have executed an order to acquire two electric frac fleets from a leading manufacturer. These new electric fleets utilize conventional pumping equipment and proven technologies that are well-known across our industry. As demand for electric solutions continues to gain momentum, ProPetro is playing a significant role in bringing new technologies and more efficient, environmentally responsible solutions to the Permian Basin." Sledge added, "We are in discussions with several customers regarding multi-year projects that will use these electric fleets starting as early as the third quarter of 2023. With these more efficient fleets, we will help advance our customers' efforts to reduce costs and greenhouse gas emissions, while enhancing our company's competitiveness and free cash flow profile. We are also excited to bolster our services and capabilities for the benefit of our customers while equipping our ProPetro teammates with the best tools to drive sustainable value creation through the ongoing multi-year upcycle."

07:49 EDT Adidas CEO Kasper Rorsted to step down in 2023 - Adidas AG's Supervisory Board announces today that it has initiated a CEO transition. Kasper Rorsted, CEO of adidas, and the Supervisory Board have mutually agreed upon that Kasper Rorsted will hand over the CEO position during the course of 2023. The search for a succession has started. Kasper Rorsted will remain CEO until a successor has been appointed. Jointly with the Supervisory Board and the Management Board he will ensure a smooth transition at the helm of the company.

07:40 EDT Winners CEO says next goal is to raise funding to carry out gameplan - Winners announced that its CEO, Wayne Allyn Root has issued a shareholder's letter to update shareholders, which read in part, "We already have the crown jewel of sports gaming in place and under lock and key. That would be yours truly. Wayne Allyn Root has been the biggest brand name in sports gambling for decades. I started as "Jimmy the Greek's" television partner at age 27 on CNBC. I set records for picking point spread winners on five television shows at FNN Sports. After going into private business selling my sports handicapping advice, millions of American sports bettors called for my advice...None of our competitors has a nationally known celebrity or personality to match the Wayne Allyn Root brand. So, we believe that we start with that advantage over our competitors. The Wayne Allyn Root brand is the exclusive property of VegasWinners. I certainly believe in the company. I am the largest individual shareholder of the parent public company Winners Inc. I've never sold one share of stock...All that's missing now is a media and marketing platform, so that millions of sports bettors get to know the brand VegasWinners, and most importantly, know where to go to see, hear and purchase our professional research, analysis, advice, data, entertainment and predictions. In other words, we need to let the world know we are here and open for business. That's precisely the use of this next round of funding- for building our marketing funnel and media/branding platform...With our new management/marketing team, combined with our new acquisition The Longshot Report, we are now approved to run ads with Google, Facebook and Instagram- valuable online marketing platforms we did not have last year. One more challenge in 2021 to mention. Although many states had legalized sports gaming in the past year, they were not open for business yet, or open only with a handful of places to gamble. The industry just wasn't quite ready last year...The real start for vibrant, legal sports gaming in America begins with the start of this coming football season...We believe we now have everything else in place to build the leading sports information and prediction company in America...We have found the ideal marketing team with a combined 50-years-experience in both online gaming and sports gaming marketing. Now, we will begin an effort to "roll up" sports handicapping companies and web sites, as well as real-time odds sites. Our first acquisition is Longshot Sports- a fully operating and profitable sports handicapping company with several hundred thousand dollars in annual revenues...We are also in the search process right now for signing famous brand name former NFL stars to join the Wayne Allyn Root brand on our video podcasts, to attract the attention of sports fans and bettors to VegasWinners."

07:34 EDT Vitalhub enters licensing agreement with Bolton NHS Foundation Trust - VitalHub announced a licensing agreement of subsidiary Intouch with Health's digital, at-home pre-op solutions, Synopsis Home and Synopsis iQ, to the Bolton NHS Foundation Trust. This agreement is a new customer contract, further expanding the Company's presence across the National Health Service, and will provide Bolton with access to Intouch's award-winning Synopsis Home and iQ products. This sale responds to a need identified by Bolton NHS Foundation Trust to alleviate their elective care backlog, increasing operational efficiency and throughput. The Trust needed a solution to enable departments to be more efficient to cope with the additional surgeries required to work toward clearing the elective backlog, and chose the Company's products to address these challenges.

07:33 EDT Vodafone to sell Vodafone Hungary for EUR 1.8B - Vodafone Group has entered into heads of terms with 4iG Public Limited Company and Corvinus Zrt in relation to the potential sale of 100% of Vodafone Hungary for a total cash consideration equivalent to an enterprise value of EUR 1.8B. This represents a multiple of 9.1x Adjusted EBITDAaL for the 12-month period ending 31 March 2022, Vodafone said in a statement. Nick Read, Chief Executive of Vodafone, said: "The Hungarian Government has a clear strategy to build a Hungarian owned national champion in the ICT sector. This combination with 4iG will allow Vodafone Hungary, which has a proud history of success and innovation in the country, to play a major role in the future growth and development of the sector as a much stronger scaled and fully converged operator. The combined entity will increase competition and have greater access to investment to further the digitalisation of Hungary." The transaction is subject to completion of confirmatory due diligence, the Parties entering into binding transaction documentation and obtaining regulatory approval. The Parties are targeting completion by the end of 2022. Vodafone's shared services business in Hungary - VOIS - is not included in the transaction perimeter and it will continue to provide services to Vodafone's other operating companies.

07:31 EDT Conagra Brands appoints Tracy Schaefer as Chief Information Officer - Conagra Brands announced the appointment of Tracy Schaefer to senior vice president and Chief Information Officer, effective today, August 22. Tracy joined Conagra in 2001 as a financial analyst and has served in a variety of leadership roles in multiple functional areas as well as transformative, enterprise-wide initiatives. She attended Drake University where she earned her degree in accounting and serves on the board of the Institute of Career Advancement.

07:27 EDT Marimaca Copper appoints Leonardo Hermosilla as VP, projects - Marimaca Copper welcomes Leonardo Hermosilla to the Team as Vice President, Projects. In addition, Marimaca announces an update on various project development workstreams at the Marimaca Copper Project. Highlights: Hermosilla will provide senior technical leadership as the Marimaca Project advances towards the 2023 Feasibility Study and a construction decision; Hermosilla will be based out of Marimaca's Santiago, Chile office; Hermosilla is a global mining executive and brings over 30 years of experience in mine development and construction to Marimaca. 2022 Drilling Campaigns Now Complete: The 2022 Infill and MAMIX drilling campaigns were completed on August 18th 2022, with remaining results pending final assays; 2022 Infill and MAMIX programs totalled 38,570m across 177 drill holes; Geological interpretation and resource modelling is currently underway ahead of the planned 2022 Mineral Resource Update expected in late Q3; The 2022 MRE will capture drilling data completed up to June 30th, 2022, with the balance of the infill drilling to be captured in a subsequent MRE planned for early 2023. Water Engagement Update; Significant progress has been made on negotiations with potential seawater suppliers located in the Bay of Mejillones to secure a seawater supply option for the Marimaca Project; Marimaca is targeting completion of the water supply option, which guarantees seawater supply for the Marimaca Project, by year-end 2022. MAMIX Transitional and Primary Copper Extraction Concept Study: Marimaca is currently completing a proof-of-concept study led by 5Q Technologies, a privately-help specialist mineral processing company based in Santiago, Chile; The study aims to evaluate the potential for improving and optimizing the recovery of the deeper transitional material located in the MAMIX-zone, the depth extension to the Marimaca Oxide Deposit; A proof-of-concept study is currently underway with initial laboratory results expected in the near term. Marimaca and 5Q may then elect to advance to a next phase of study with a larger sample size; The 5Q study will supplement the Phase 5 Metallurgical Program which represents the culmination of a rigorous, bankable-level 5-phase metallurgical program at the MOD. Geotechnical and Condemnation Drilling: Marimaca has now completed the 2022 geotechnical diamond drilling campaign which was executed alongside the 2022 Infill and MAMIX campaigns; 2022 geotechnical and geological campaign totalled 3,000m across 13 diamond drill holes; Data from the 2022 geotechnical campaign will be used in the 2023 Feasibility Study and relevant permitting submissions planned for 2023; Planning and budgeting are currently underway for the condemnation drilling program across key infrastructure areas. Hayden Locke, President & CEO of Marimaca Copper, commented: "I am very excited to welcome Leonardo to the team as we start our transition to developer and, eventually, operator of the Marimaca Oxide Deposit. He brings enormous experience in mine development and will provide important technical leadership as Marimaca moves toward production. The 2022 infill drilling campaign is now complete and we remain confident that the first mineral resource update, towards the end of September, will deliver a step change in the scale of the Marimaca Project. We continue to make good progress with the various work programs aimed at moving the project towards production, and we look forward to updating the market on these as they're completed."

07:21 EDT Neo Performance, Hudson Resources sign agreement for exploration license - HUDSON RESOURCES and NEO PERFORMANCE MATERIALS are pleased to announce that the parties have executed a binding agreement whereby Neo will acquire from Hudson an exploration license covering the Sarfartoq Carbonatite Complex in southwest Greenland. The Project hosts a mineral deposit that is enriched in neodymium and praseodymium, two essential elements for rare earth permanent magnets used in electric vehicles, wind turbines, and high-efficiency electric motors and pumps that help reduce greenhouse gas emissions. Located just 60 kilometers from the international airport in Kangerlussuaq, the Project is close to tidewater and a major port facility and is directly adjacent to some of the best hydroelectric potential in Greenland. Neo, through a special purpose entity, plans to explore and develop the Sarfartoq Project to further diversify its global sourcing of rare earth ore and to expand the rare earth supply chains that feed Neo's rare earth separation facility in Estonia. That facility was recently awarded a Gold Medal for its sustainable practices by EcoVadis, the well-respected global sustainability auditor. Neo is also pursuing plans to break ground on a greenfield rare earth permanent magnet manufacturing plant in Estonia that is intended to provide European manufacturers with the permanent magnets needed for electric and hybrid vehicles, wind turbines, and energy-saving electric motors and pumps. The Sarfartoq Project also is a key element of Neo's "Magnets-to-Mine" vertical integration strategy. Completion of the sale of the license is subject to various conditions, including approval from the Government of Greenland for the transfer of the License, expected to take approximately six months, and approval of the TSX Venture Exchange on the part of Hudson. Neo intends to assign its rights under the Agreement to an SPE controlled by Neo that would hold the License and continue exploration and ultimately extraction of the rare earth elements on the Project. The key terms of the Agreement are as follows: Hudson receives a nonrefundable initial cash payment of US$250,000 upon signing of the Agreement. Upon receipt of approval from the Greenland government, Hudson will transfer the License to Neo or the SPE. Hudson will receive an additional US$3,250,000 upon closing of the transaction. If within five years from the date of closing of the transaction the SPE transfers the License, or there is a change in control of the SPE pursuant to an acquisition or merger, then Hudson will receive 5% of the total consideration received by the SPE in connection with such transfer, or the SPE conducts an initial public offering on a stock exchange, then Hudson will receive 5% of the fully diluted equity interests in the SPE immediately prior to the IPO. The License covers the large Sarfartoq carbonatite complex that hosts Hudson's ST1 REE project and the Nukittooq Niobium-Tantalum project. The REEs on the Property have a high ratio of neodymium and praseodymium at 25%-40% of Total Rare Earth Oxides. Hudson completed a Preliminary Economic Assessment on the ST1 project in November 2011 that outlined a National Instrument 43-101 compliant resource containing 27 million kilograms of neodymium oxide and 8 million kilograms of praseodymium oxide. Three kilometers east of the ST1 Zone is another high-grade zone that hosts one of the rare earth industry's highest-known ratios of neodymium oxide to Total Rare Earth Oxide -- 45% -- as shown by Hudson's original mineralogical work. Neo and the SPE expect to conduct additional exploratory drilling and other work to move the Project forward to eventual commercial operation. Neo also intends to enter into an offtake agreement with the SPE with rights to purchase 60% of the ore or mineral concentrate produced from the Project. Closing of the transaction is subject to customary regulatory approvals by the TSX-V and the Greenland government.

07:18 EDT Ascot announces assay results from drill program at Premier Gold Project - Ascot Resources announced the second batch of assay results from the 2022 exploration drill program at the Company's Premier Gold Project, located on Nisga'a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. These results are from surface exploration drilling at the emerging Sebakwe Zone, approximately 600 metres east of the past-producing Premier mill. Highlights from the drill results include: 11.83 g/t Au and 56.3 g/t Ag over 2.73m, including 20.10 g/t Au and 82.4 g/t Ag over 1.40m, from a depth of 335.47m in hole P22-2394; 6.33 g/t Au and 6.6 g/t Ag over 3.20m, including 11.25 g/t Au and 10.7 g/t Ag over 1.60m, from a depth of 290.10m in hole P22-2396; 8.25 g/t Au and 15.7 g/t Ag over 1.45m from a depth of 290.55m in hole P22-2400. The Company had initially planned on drilling 10 new holes totaling approximately 4,000 metres at Sebakwe as a part of the 2022 exploration drilling program, but based on encouraging visual indications of mineralization and structure, this was increased to 15 holes totaling 6,110 metres. Following the first batch of six drill holes released previously which included bonanza-grade gold of 193 g/t, this release summarizes results from the remaining nine surface drill holes totaling 3,633 metres. Derek White, President and CEO of Ascot commented, "Following on our previous drilling success at Sebakwe, we have now increased the mineralized strike length fivefold from 70 metres to 350 metres, with mineralization still open in several directions. In just 15 holes drilled this season, we have achieved our main objectives in establishing the high-grade tenor, identifying more coarse, visible gold, and growing the mineralized zone with step-out drilling. We look forward to the future of the Sebakwe Zone and continuing to demonstrate it as an accretive, near-mine exploration success and potential to grow our resource base for development near planned underground infrastructure. We have advanced underground development at Big Missouri over 450 metres to date and have reached initial mineralized areas, allowing for detailed face sampling. Drilling is ongoing at Big Missouri and we have been encouraged by multiple occurrences of visible gold in the drill core. We will report the corresponding assays as they become available."

07:15 EDT Aslan Pharmaceuticals to host hybrid R&D Day - ASLAN Pharmaceuticals announced that it will be hosting a R&D Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York, NY. The event will include presentations from management as well as Key Opinion Leaders in dermatology, Peter A. Lio, MD of Northwestern University Feinberg School of Medicine, and Shawn Kwatra, MD of Johns Hopkins University, who will discuss the emerging unmet needs, therapeutic landscape and molecular mechanisms underlying AD. ASLAN's leadership team including Carl Firth PhD, Stephen Doyle, Alex Kaoukhov MD, and other members of the senior R&D management team will discuss the pipeline portfolio led by eblasakimab, a potential novel, first-in-class monoclonal antibody that targets the IL-13 receptor alpha1 subunit being developed for the treatment of moderate-to-severe AD. The event will provide a comprehensive update on the eblasakimab development program, including: Translational data on eblasakimab's unique mechanism of action; Clinical data from the Phase 1b proof-of-concept study of eblasakimab; Overview of eblasakimab's development strategy and path to market; Update on the latest in AD research.

07:12 EDT Else Nutrition launches on Amazon Canada - ELSE NUTRITION HOLDINGS announces that it has launched in Canada on Amazon.ca. Else launched on Amazon.com in the United States in September 2020, and in less than 2 years grew to an annual business of 4m CAD. In this short period, Else's offerings grew from a single SKU to three product lines with more than 15 SKUs. In its Q2 2022 financial results Else reported outstanding results on the Amazon platform - 84% QoQ sales increase and doubling its loyal subscriber community on the platform from 1,000 to almost 2,000. The Else Amazon.ca launch includes a full range of Canadian compliant products with bilingual compliant packaging, including a Toddler nutrition product, Kids shakes in Vanilla and Chocolate flavors, and to be soon followed by Supper Cereals for babies from 6 months and older in a few flavors.

07:09 EDT LGI Homes announces opening of ShadowGlen - LGI Homes announced the opening of ShadowGlen, its newest Terrata Homes community in the Austin market. Located in the historic town of Manor, this amenity-rich community offers homebuyers a variety of new, upgraded homes with spacious layouts and designer finishes.

07:08 EDT Bruker announces new scientific capabilities for cell biology research - At the ICMRBS 2022 Conference, Bruker announces a new 8 mm 15N TROSY Cryoprobe for enabling novel NMR functional structural biology investigations into larger globular proteins and protein complexes. The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins or protein regions that often play key roles in signaling pathways via phosphorylation, e.g. in cancer. The new 8 mm 15N TROSY Cryoprobe provides twice the sensitivity of previous 5 mm detection, and 50% greater 13C sensitivity at 800 MHz. It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances. Bruker also announces the technology introduction of a novel 160 kHz Ultra-fast spinning Magic Angle Spinning NMR probe for advancements in solid-state membrane protein, prion, and aggregates research. Moreover, as announced at Euromar 2022, Bruker has received three orders for compact 1.0 GHz NMR systems from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan, the Precision Medicine and Metabolism Lab at CIC bioGUNE, and the BioNMR Group at Universitat de Barcelona, both in Spain.

07:06 EDT Tonix initiates enrollment in Phase 2 PREVAIL study of TNX-102 SL - Yonix Pharmaceuticals Holding announced that the first participant was enrolled in the Phase 2 PREVAIL study of TNX-102 SL1 as a potential treatment for a subset of patients with Long COVID syndrome whose symptoms overlap with fibromyalgia. Long COVID is known officially as Post-Acute Sequelae of COVID-19.

07:05 EDT Fennec closes $5M investment from Petrichor - Fennec Pharmaceuticals completed the first closing of $5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management. Under the terms of the investment agreement, an additional $20 million is to be funded upon the potential U.S. Food and Drug Administration approval of PEDMARK by September 30, 2022 and satisfaction of other closing conditions. Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement. In connection with the first closing, the Company repaid in full its secured indebtedness with Bridge Bank.

07:04 EDT Honeywell's Solstice yf UV available in NAPA Auto Parts stores in U.S. - Honeywell announced that its new Solstice yf UV - a low-global-warming-potential, or GWP, refrigerant incorporating ultraviolet, or UV, dye for leak detection support in automobile air conditioning systems - is now available at all participating NAPA Auto Parts stores across the United States. This is the first time Solstice yf refrigerant with UV dye will be available in the aftermarket. Honeywell's Solstice yf UV is manufactured in the United States and is commercially available today at participating NAPA Auto Parts stores in 8-ounce cans as well as in 10- and 25-pound cylinders.

07:02 EDT Travere, CSL announce EMA acceptance of CMA application for sparsentan - Travere Therapeutics (TVTX) and CSL Vifor (CSLLY) announced that the EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgAN, a rare kidney disorder and leading cause of end-stage kidney disease. The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023 The EMA filing is supported by positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgAN, as well as supportive data from additional clinical studies. The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance. After 36 weeks of treatment, patients receiving sparsentan achieved a mean reduction in proteinuria from baseline of 49.8 percent, compared to a mean reduction in proteinuria from baseline of 15.1 percent for irbesartan-treated patients. Preliminary results at the time of the interim assessment suggested that sparsentan had been generally well-tolerated to date in the study and consistent with its overall observed safety profile. If approved, sparsentan would receive CMA in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway. Sparsentan is currently also being evaluated in the pivotal Phase 3 DUPLEX Study for the treatment of focal segmental glomerulosclerosis, another rare progressive kidney disorder and leading cause of end-stage kidney disease. Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN and FSGS in Europe and in the U.S.

07:02 EDT Bausch Health transfers Bausch + Lomb shares to its subsidiary - Bausch Health Companies has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing wholly-owned unrestricted subsidiary of the Company. Common shares in an amount equal to approximately 50.1% of Bausch + Lomb continue to be held by a wholly-owned restricted subsidiary of the Company, and Bausch + Lomb itself remains a restricted subsidiary of the Company. The Company, through its subsidiaries, continues to hold the same number of shares of Bausch + Lomb as it did prior to the Internal Transfer, which in the aggregate comprises approximately 88.7% of the issued and outstanding shares of Bausch + Lomb. The Internal Transfer is consistent with the Company's commitment to the separation of Bausch + Lomb and provides the Company with strategic flexibility while it evaluates all relevant factors and considerations relating to the separation of Bausch + Lomb. The separation of Bausch + Lomb is contingent on the expiry of customary lockups related to the initial public offering of Bausch + Lomb, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals.

06:58 EDT Pharvaris drops 18% to $14.99 after FDA clinical hold of PHA121 trials in U.S.

06:51 EDT Pharvaris announces FDA clinical hold on PHA121 clinical trials in U.S. - Pharvaris announced that the U.S. FDA verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug applications for the treatment of HAE. The FDA indicated it will provide a formal clinical hold letter to Pharvaris in approximately 30 days. The company plans to provide additional updates following interactions with the FDA. "We are fully committed to working closely with the FDA to address the agency's concerns," said Berndt Modig, CEO of Pharvaris. "Pharvaris remains dedicated to providing new therapeutic choices for the treatment of HAE and is working diligently to bring PHA121 to people living with HAE."

06:47 EDT BWX Technologies names Robert Duffy as chief administrative officer - BWX Technologies (BWXT) has appointed Robert Duffy as senior vice president and chief administrative officer. In this role, he will have full responsibility for human resources and a number of other business support functions. Duffy most recently served as senior vice president and chief human resources & administration officer for L3Harris Technologies (LHX).

06:34 EDT Teleflex to acquire Standard Bariatrics for upfront cash payment of $170M - Teleflex announced it has entered into a definitive agreement to acquire Standard Bariatrics, which has commercialized an innovative powered stapling technology for bariatric surgery. Under the terms of the agreement, Teleflex will acquire Standard Bariatrics for an upfront cash payment of $170M at closing, with additional consideration of up to $130M payable upon the achievement of certain commercial milestones. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed early in the fourth quarter. The Titan SGS was commercially launched in the third quarter of 2021. Standard Bariatrics' revenues for 2022 are expected to be approximately $15M. For fiscal year 2022, the transaction is not expected to contribute meaningfully to Teleflex revenue and is expected to be approximately 10c dilutive to adjusted earnings per share. For fiscal year 2023, the transaction is expected to contribute between $30M-$35M of revenue and be approximately 10c-15c dilutive to adjusted earnings per share. The transaction is expected to be accretive to revenue growth and adjusted EPS thereafter. The company will provide an update to its 2022 financial outlook on its third quarter earnings conference call.

06:31 EDT Teleflex to acquire Standard Bariatrics for upfront cash payment of $170M - Teleflex announced it has entered into a definitive agreement to acquire Standard Bariatrics, which has commercialized an innovative powered stapling technology for bariatric surgery. Under the terms of the agreement, Teleflex will acquire Standard Bariatrics for an upfront cash payment of $170M at closing, with additional consideration of up to $130M payable upon the achievement of certain commercial milestones. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed early in the fourth quarter.

06:17 EDT CDC says Wendy's in several states linked to E. Coli outbreak - The C.D.C. provided an updated investigation notice on an E. Coli outbreak. A specific food has not yet been confirmed as the source of this outbreak, but many sick people reported eating sandwiches with romaine lettuce at Wendy's restaurants in Michigan, Ohio and Pennsylvania before getting sick. Based on this information, Wendy's is taking the precautionary measure of removing the romaine lettuce being used in sandwiches from restaurants in that region. Wendy's uses a different type of romaine lettuce for salads. Investigators are working to confirm whether romaine lettuce is the source of this outbreak, and whether romaine lettuce used in Wendy's sandwiches was served or sold at other businesses. Wendy's is fully cooperating with the investigation.

06:07 EDT Bright Scholar announces results of 2022 Annual General Meeting - Bright Scholar Education announced that it held its 2022 annual general meeting of shareholders on August 22, 2022. At the meeting, the shareholders resolved by ordinary resolution to ratify the appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the independent registered public accounting firm of the Company for the fiscal year ending August 31, 2022.

06:06 EDT Relief, NRx Pharmaceuticals announce tentative settlement of pending litigation - RELIEF THERAPEUTICS (RLFTF) and NRx Pharmaceuticals (NRXP) announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days. Further, the parties have agreed to stay the litigation for an additional 60 days to allow for the negotiation and execution of the definitive settlement agreement and related terms. Terms of the settlement will be reported following execution of the definitive settlement documents, but any settlement may result in a re-allocation of the development rights and licensing arrangements for aviptadil. There can be no assurance that the parties will successfully complete the proposed settlement.

06:03 EDT Genetron confirms preliminary non-binding acquisition proposal from CEO - Genetron announced that its Board of Directors has received a preliminary non-binding proposal letter, dated August 21, from Mr. Sizhen Wang, co-founder, chairman of the Board and CEO of the company to acquire all of the outstanding ordinary shares, par value $0.00002 per share of the company, including the Ordinary Shares represented by the American depositary shares of the company for 27.2c per Ordinary Share or $1.36 per ADS in cash. According to the Proposal Letter, the Proposing Buyer intends to fund the consideration payable in the Proposed Transaction with a combination of debt and equity capital. Equity financing is expected to be provided in the form of rollover equity in the Company and cash contributions from the Proposing Buyer and third party sponsors. The Board has formed a special committee consisting of two independent directors, Wing Kee Lau and Dian Kang, to evaluate and consider the Proposed Transaction as well as other potential strategic alternatives that the company may pursue. The Special Committee intends to retain advisors, including an independent financial advisor and independent legal counsel, to assist it in its evaluation. The Board cautions the company's shareholders and others considering trading the company's securities that the Board has just received the Proposal Letter and has not had an opportunity to carefully review or evaluate the proposal, or make any decision with respect to the company's response to the Proposed Transaction or any alternative strategic option that the company may pursue. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the Proposed Transaction or that this or any other transaction will be approved or consummated. The company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

05:59 EDT Mereo BioPharma sends letter to Rubric Capital Management - Mereo BioPharma sent a letter to Rubric Capital Management responding to a letter from Rubric dated August 19, in which Rubric purported to call for a General Meeting of Shareholders of Mereo and proposed to remove four of Mereo's directors and replace them with four directors nominated by Rubric. In Mereo's letter sent to Rubric, the company notified Rubric of certain deficiencies in its notice. Mereo appreciates the input of all shareholders and is prepared to engage with Rubric to help correct these deficiencies. Mereo's shareholders do not need to take any action at this time.

05:55 EDT Amcor acquires flexible packaging plant in the Czech Republic - Amcor announced that it has closed the acquisition of a world-class flexible packaging plant located in the Czech Republic. The strategic location of the site immediately increases Amcor's ability to satisfy strong demand and customer growth across its flexible packaging network in Europe. The plant is a greenfield development commissioned by DG Pack in 2019 and features state-of-the-art specialized equipment for attractive segments including coffee and pet food. The land and buildings acquired also provide the option to significantly scale up operations and establish a highly efficient production hub.

05:53 EDT Roche develops COVID-19 test for emerging variant of interest BA.2.75 - Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the latest subvariant of interest BA.2.75. The test specifically targets two of the known unique mutations in BA.2.75, which allows clear differentiation against other notable subvariants. The available research use only test, VirSNiP SARS-CoV-2 Spike 147E 152R, adds to the broad suite of COVID-19 test kits developed by Roche and TIB Molbiol, for instance for the detection of the recent BA.4 and BA.5 subvariants, as well as other mutations present in the Omicron SARS-CoV-2 variant.

05:22 EDT Cineworld says Chapter 11 filing in U.S. among strategic options - In response to media speculation, Cineworld provided an update to its announcement on August 17 regarding an "evaluation of strategic options to both obtain additional liquidity and potentially restructure its balance sheet through a comprehensive deleveraging transaction." Cineworld and Regal theaters globally are open for business as usual, the company said. The strategic options through which Cineworld may achieve its restructuring objectives include a possible voluntary Chapter 11 filing in the United States and associated ancillary proceedings in other jurisdictions as part of an orderly implementation process, the company added. Cineworld said it is in discussions with many of its major stakeholders including its secured lenders and their legal and financial advisers. "Any such filing would be expected to allow the Group to access near-term liquidity and support the orderly implementation of a fully funded deleveraging transaction," Cineworld noted. Reference Link